New Clearside Biomedical (CLSD)’s Coverage Started By Janney Capital On Jun 29, 2018.

June 29, 2018 - By Alice Reed

What’s Janney Capital’s Current Rate of Clearside Biomedical (CLSD)

On Thursday morning, a coverage started with Clearside Biomedical (CLSD) that has Buy rating at Janney Capital, reports.

Clearside Biomedical, Inc. (NASDAQ:CLSD) Ratings Coverage

A total of 7 analysts rate Clearside Biomedical (CLSD) as follows: 7 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (CLSD) has 9 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Tuesday, March 6 the firm earned “Overweight” rating by JP Morgan. On Tuesday, March 6 the firm has “Buy” rating by Wedbush given. In Wednesday, February 7 report Wedbush maintained it with “Buy” rating and $27.0 target. On Tuesday, February 20 the stock of Clearside Biomedical, Inc. (NASDAQ:CLSD) earned “Buy” rating by Cowen & Co. On Tuesday, March 20 the firm has “Buy” rating by Wedbush given. On Monday, March 5 the stock has “Buy” rating by Stifel Nicolaus.

Ticker’s shares touched $10.87 during the last trading session after 1.21% change.Clearside Biomedical, Inc. has volume of 42,412 shares. Since June 29, 2017 CLSD has risen 77.87% and is uptrending. CLSD outperformed by 65.30% the S&P500.

On August, 8 is anticipated Clearside Biomedical, Inc. (NASDAQ:CLSD)’s earnings report, RTT reports. Analysts forecast $-0.57 earnings per share. That’s $0.03 down or 5.56 % from 2017’s earnings of $-0.54. -8.06 % EPS growth is what analysts predict. $-0.62 earnings per share was reported for previous quarter.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye.The firm is valued at $347.26 million. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.Last it reported negative earnings. The firm also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases.

For more Clearside Biomedical, Inc. (NASDAQ:CLSD) news released recently go to:,,, or The titles are as follows: “58 Biggest Movers From Yesterday” released on June 01, 2018, “Mid-Afternoon Market Update: J.Jill Climbs On Earnings Beat; Scpharmaceuticals Shares Fall” on May 31, 2018, “Clearside Bio completes enrollment in late-stage study of CLS-TA in retinal vein occlusion” with a publish date: June 13, 2018, “Clearside Biomedical to Participate in 2018 JMP Securities Life Sciences Conference” and the last “44 Stocks Moving In Thursday’s Mid-Day Session” with publication date: May 31, 2018.

Clearside Biomedical, Inc. (NASDAQ:CLSD) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.